Best FMCG Stocks In India 2024

Date:

Share post:

Hindustan Unilever Ltd

Market Cap  ₹ 606,101 Cr.

Debt  ₹ 1,043 Cr.

ROE  18.4 %

Sales growth  13.2 %

EPS  ₹ 39.0

Industry PE  62.3

Stock P/E  66.0

ROCE  24.4 %

Promoter holding  61.9 %

Pledged percentage  0.00 %

PEG Ratio  4.22

Net profit  ₹ 9,183 Cr.

Return on Equity:

10 Years: 45%

5 Years: 36%

3 Years: 28%

Last Year: 18%

Compounded Profit Growth:

10 Years: 13%

5 Years: 16%

3 Years: 13%

TTM: 11%

Compounded Sales Growth

10 Years: 8%

5 Years: 10%

3 Years: 10%

TTM: 13%

PROS:

  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 28.4%
  • Company has been maintaining a healthy dividend payout of 96.4%

CONS:

  • Stock is trading at 12.4 times its book value
  • The company has delivered a poor sales growth of 9.60% over the past five years.
  • Promoter holding has decreased over last 3 years: -5.28%

Procter & Gamble Hygiene and Health Care Ltd

Market Cap  ₹ 45,860 Cr.

Debt  ₹ 5.10 Cr.

ROE  79.3 %

Sales growth  9.14 %

EPS  ₹ 177

Industry PE  62.3

Stock P/E  79.6

ROCE  110 %

Promoter holding  70.6 %

Net profit  ₹ 576 Cr.

PEG Ratio  14.3

Pledged percentage  0.00 %

Return on Equity:

10 Years: 44%

5 Years: 58%

3 Years: 62%

Last Year: 79%

Compounded Profit Growth:

10 Years: 12%

5 Years: 6%

3 Years: 11%

TTM: -12%

Compounded Sales Growth:

10 Years: 12%

5 Years: 11%

3 Years: 10%

TTM: 9%

PROS:

  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 61.7%
  • Company has been maintaining a healthy dividend payout of 109%

CONS:

  • Stock is trading at 62.0 times its book value
  • The company has delivered a poor sales growth of 11.0% over the past five years.

 

Colgate-Palmolive (India) Ltd

Market Cap  ₹ 44,494 Cr.

Debt  ₹ 83.0 Cr.

ROE  74.4 %

Sales growth  3.30 %

EPS  ₹ 38.8

Industry PE  62.3

Stock P/E  42.0

ROCE  92.0 %

Promoter holding  51.0 %

Net profit  ₹ 1,055 Cr.

PEG Ratio  3.15

Pledged percentage  0.00 %

Return on Equity:

10 Years: 65%

5 Years: 60%

3 Years: 67%

Last Year: 74%

Compounded Profit Growth:

10 Years: 9%

5 Years: 13%

3 Years: 13%

TTM: -1%

Compounded Sales Growth:

10 Years: 7%

5 Years: 5%

3 Years: 5%

TTM: 3%

PROS:

  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 67.4%
  • Company has been maintaining a healthy dividend payout of 98.0%

CONS:

  1. Stock is trading at 25.8 times its book value
  2. The company has delivered a poor sales growth of 5.07% over the past five years.

 

Related articles

Will Trump’s Tariffs Expose India’s Drug Safety Concerns?

What’s Happening? India’s pharmaceutical industry could face a major challenge as Trump’s new tariffs and stricter drug safety norms...

ERIS Lifesciences: Smart Investment or Hidden Red Flags?

ERIS Lifesciences Ltd: Growth or Red Flags? 🤔📈 A significant momentum is visible in an important pharmaceutical stock—ERIS Lifesciences...

Jindal Worldwide Ltd – A Potential Red Flag in Shareholding Pattern?

Jindal Worldwide Ltd operates in the textiles sector, specializing in the manufacturing of denim fabric, premium shirting's, yarn...

Mastering Stock Selection: Pattern, Volume & Fundamental Analysis Combined

When a stock forms a pattern with volume, it indicates significant market activity, whether it's accumulation or a...
WhatsApp chat